Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
83.81
-2.92 (-3.37%)
At close: Apr 28, 2026, 4:00 PM EDT
84.60
+0.79 (0.94%)
After-hours: Apr 28, 2026, 6:10 PM EDT
Nektar Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Nektar Therapeutics stock have an average target of 146.67, with a low estimate of 95 and a high estimate of 185. The average target predicts an increase of 75.00% from the current stock price of 83.81.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nektar Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $123 → $151 | Strong Buy | Maintains | $123 → $151 | +80.17% | Apr 21, 2026 |
| Wedbush | Wedbush | Hold Maintains $70 → $95 | Hold | Maintains | $70 → $95 | +13.35% | Apr 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $165 → $185 | Strong Buy | Maintains | $165 → $185 | +120.74% | Apr 20, 2026 |
| BTIG | BTIG | Strong Buy Maintains $151 → $178 | Strong Buy | Maintains | $151 → $178 | +112.39% | Apr 20, 2026 |
| Wedbush | Wedbush | Hold Initiates $70 | Hold | Initiates | $70 | -16.48% | Mar 24, 2026 |
Financial Forecast
Revenue This Year
42.20M
from 55.23M
Decreased by -23.60%
Revenue Next Year
36.64M
from 42.20M
Decreased by -13.18%
EPS This Year
-10.12
from -9.73
EPS Next Year
-12.38
from -10.12
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 47.7M | 48.7M | ||||||
| Avg | 42.2M | 36.6M | ||||||
| Low | 23.5M | 7.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -13.7% | 15.5% | ||||||
| Avg | -23.6% | -13.2% | ||||||
| Low | -57.4% | -81.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | -7.77 | -9.19 | |||||
| Avg | -10.12 | -12.38 | |||||
| Low | -13.26 | -15.24 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | - | |||||
| Avg | - | - | |||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.